The GPNMB Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human osteosarcoma 143B cell line, featuring targeted disruption of the GPNMB gene. This polyclonal pool serves as a heterogeneous loss-of-function model, minimizing clonal bias and enabling robust characterization of GPNMB-mediated cell adhesion, signal transduction, and osteogenic differentiation within a physiologically relevant osteosarcoma background.
The 143B cell line is a widely used osteosarcoma model with osteoblast-like precursor properties and the capacity for osteogenic differentiation. Originating from a human osteosarcoma, these cells recapitulate key features of bone biology and cancer pathology, including tumorigenicity and osteolytic bone lesion formation, making them particularly valuable for research into osteosarcoma progression, bone metastasis, and osteoblast function. The introduction of the GPNMB knockout into this line offers a targeted tool to dissect gene function in these contexts.
GPNMB encodes a transmembrane glycoprotein that functions as a ligand for integrin receptors such as ITGA5/ITGB1, CD44, and HSPG2, mediating cell adhesion and triggering intracellular signaling. Upon engagement, GPNMB activates focal adhesion kinase (FAK) and SRC, leading to phosphorylation of ERK1/2 and AKT, which drives cell proliferation, survival, and osteogenic differentiation. GPNMB expression is transcriptionally regulated by MITF and induced by TGF-beta1 and BMP2, integrating its function into TGF-beta and BMP pathways. Moreover, GPNMB intersects with the Wnt pathway via components like Wnt3a, Frizzled, LRP5, and beta-catenin, further linking it to osteogenic and oncogenic signaling networks.
In 143B cells, disruption of GPNMB is anticipated to impair integrin-mediated adhesion and downstream FAK/SRC/ERK1/2 and AKT signaling, attenuating osteogenic differentiation and metastatic potential. This knockout model allows interrogation of GPNMB’s contribution to bone formation, tumor growth, and bone metastasis, exploiting the 143B cell line’s inherent osteoblast-like characteristics. Researchers can examine how loss of GPNMB modulates responses to osteogenic cues such as TGF-beta1 and BMP2, and delineate the gene??s role in the crosstalk between adhesion and growth factor pathways.
Applications include biochemical analyses such as Western blotting for GPNMB and phospho-ERK/AKT, RT-qPCR for osteogenic markers, and immunofluorescence for protein localization. Functional assays include cell adhesion, migration, and invasion studies to assess GPNMB??s role in cancer cell motility. Osteogenic differentiation assays (ALP staining, Alizarin Red) and drug sensitivity testing further support bone biology and therapeutic development research. These polyclonal knockout cells are a versatile resource for target validation and mechanistic studies in osteosarcoma and metastasis. For further details, please contact Ascent Research.
